Windtree Therapeutics, a Nasdaq-listed biotech firm, announced its plan to purchase up to $700 million in BNB, the fifth-largest digital currency, following its recent all-time high. The company is raising $520 million to fund these acquisitions, having previously aimed to acquire $200 million in BNB. It will partner with crypto exchange Kraken for asset custody. The funding will be sourced from a $500 million equity line of credit with an unnamed institutional investor and a $20 million stock purchase agreement with Build and Build Corp. CEO Jed Latkin emphasized the importance of securing additional funds for expanding its cryptocurrency investments, reflecting a growing trend of publicly traded companies adding digital assets to their balance sheets. Despite a slight drop in Windtree's stock recently, it has risen significantly by 162% over the past month. Other firms, like Chinese blockchain infrastructure company Nano Labs, are also investing heavily in BNB, indicating a broader acceptance of cryptocurrency in corporate treasury strategies.

Source šŸ”—